Kalamazoo County will continue funding GLP-1 drugs as part of its employee health coverage, but a co-pay will now be imposed on some employees. The announcement came on August 7, 2026, and preserves the county's support for the medication class. Specifics such as the size of the co-pay, the…
Kalamazoo County will continue to fund GLP-1 drugs, while adding a co-pay requirement for some employees. The county's decision was announced on August 7, 2026.
The move keeps the medication class in the county's employee health plan. Funding for GLP-1 drugs will not be cut. Instead, the county is changing how some employees share in the cost.
The county's support for GLP-1 drugs remains in place. The announcement did not remove these medications from coverage. Employees who use these drugs will still have the county as the payer.
The decision does not apply a co-pay across the entire workforce. Only some employees will be subject to the new requirement. Other employees are not part of the change.
A co-pay will now be imposed on certain employees. The announcement did not identify which employees those are. It also did not give the dollar amount of the co-pay.
The effective date of the co-pay was not mentioned. The county has not spelled out the full details of the cost-sharing measure. Affected employees will have an additional out-of-pocket expense when the co-pay takes effect.
For the county, the co-pay shifts part of the cost to a portion of employees. The county continues to pay for GLP-1 drugs overall. The benefit remains funded.
Several details are missing from the announcement. No specific employee categories were named. No co-pay amount was provided. No start date was given.
What is certain is that GLP-1 funding will continue. The county is not ending its financial support for the drug class. The only announced change is the co-pay for a portion of employees.
Employees covered by the county plan should await further communication about which groups are affected and what the co-pay will cost. Until then, the core policy stands: GLP-1 drugs remain funded, with a co-pay introduced for some employees.
Peptides referenced: GLP-1.
Related reading: Amazon Pharmacy starts filling $50 Medicare GLP-1 prescriptions, Postbiotic Supplement Boosts Body's Own GLP-1 and Weight Loss, Novo Nordisk CFO Covers Oral Wegovy Rollout and Beyond, Novo Nordisk Names First EU Country for Wegovy Pill Launch.